Great news about the extension of a Phase 1 trial of PV-10 "Rose Bengal" based on the initial results led by Prof Tim Price of Queen Elizabeth Hospital Adelaide which were presented this week at ESMO (European Society of Medical Oncology).
This single-center Phase 1 study is evaluating the potential safety, tolerability and preliminary efficacy of PV-10 in patients with metastatic NETs of the liver. Comprehensive clinical data is planned to be presented at a medical conference in the first quarter of 2019.
Click here for the full announcement from Provectus Biopharmaceuticals Inc
